Because early treatment choice is critical in first-episode schizophrenia-spectrum disorders (FES), this metaanalysis compared efficacy and tolerability of individual second-generation antipsychotics (SGAs) with firstgeneration antipsychotics (FGAs) in FES. We conducted systematic literature search (until 12 December 2010) and meta-analysis of acute, randomized trials with o1 FGA vs. SGA comparison ; patients in their first episode of psychosis and diagnosed with schizophrenia-spectrum disorders ; available data for psychopathology change, treatment response, treatment discontinuation, adverse effects, or cognition. Across 13 trials (n=2509), olanzapine (seven trials) and amisulpride (one trial) outperformed FGAs (haloperidol : 9/13 trials) in 9/13 and 8/13 efficacy outcomes, respectively, risperidone (eight trials) in 4/13, quetiapine (one trial) in 3/13 and clozapine (two trials) and ziprasidone (one trial) in 1/13, each. Compared to FGAs, extrapyramidal symptom (EPS)-related outcomes were less frequent with olanzapine, risperidone and clozapine, but weight gain was greater with clozapine, olanzapine and risperidone. Pooled SGAs were similar to FGAs regarding total psychopathology change, depression, treatment response and metabolic changes. SGAs significantly outperformed FGAs regarding lower treatment discontinuation, irrespective of cause, negative symptoms, global cognition and less EPS and akathisia, while SGAs increased weight more (p<0.05-0.01). Results were not affected by FGA dose or publication bias, but industry-sponsored studies favoured SGAs more than federally funded studies. To summarize, in FES, olanzapine, amisulpride and, less so, risperidone and quetiapine showed superior efficacy, greater treatment persistence and less EPS than FGAs. However, weight increase with olanzapine, risperidone and clozapine and metabolic changes with olanzapine were greater. Additional FES studies including broader-based SGAs and FGAs are needed.
Introduction
Schizophrenia is a chronic, debilitating mental disorder (van Os and Kapur, 2009 ) with a life-time prevalence of 0.30-0.66 %, increasing to 2.3 % when including other psychotic disorders (Perala et al. 2007) . Schizophrenia is associated with significant medical co-morbidity and mortality, with an average life-span shortening by 10-30 yr (Goff et al. 2005) . Illness onset typically occurs in late adolescence/young adulthood and lifetime treatment is required to maintain/improve social functioning and prevent symptom relapse, which causes significant public health and economic burden. Successful firstepisode schizophrenia (FES) treatment is crucial to minimize social and vocational deterioration (Robinson et al. 2004) .
Antipsychotics are the mainstay of schizophrenia treatment (Kane, 1999 ; van Os and Kapur, 2009 ). Typical or first-generation antipsychotics (FGAs) and atypical or second-generation antipsychotics (SGAs) are effective for positive symptoms. However, as a class, FGAs cause more extrapyramidal motor symptoms (EPS) and tardive dyskinesia (TD) than SGAs, whereas SGAs generally cause more weight gain and cardiometabolic adverse effects (Leucht et al. 2009 ). Recent large randomized controlled trials (RCTs ; Lieberman et al. 2005 ; Jones et al. 2006 ) and a meta-analysis (Leucht et al. 2009 ) of FGA vs. SGA RCTs in chronic schizophrenia suggested no significant efficacy/effectiveness differences, or few non-clozapine SGA advantages with effect size (ES) differences of only 0.1-0.3. However, RCTs in chronic schizophrenia have limitations, including confounding effects of prior medication use, possible over-representation of only partially responsive or treatment nonadherent patients and a tendency of recruiting patients with low pre-study functioning levels, potentially reducing overall treatment responsiveness. Conversely, some trials might enrol more responsive patients consenting to RCTs.
Compared to chronic patients, FES patients generally have higher response rates (Robinson et al. 1999 ; Tohen et al. 2000) , require lower antipsychotic doses and are more sensitive to adverse effects (Robinson et al. 2005) . Hence, FES studies offer the unique opportunity to examine antipsychotic therapeutic and adverse effects in more representative patients in whom important initial treatment effects take place. While in FES patients, therapeutic and adverse response patterns are largely unknown, treatment recommendations must be based upon research findings, rather than past treatment history. RCTs in FES have flourished in the past decade. However, there is still a debate regarding the comparative efficacy and effectiveness of FGAs vs. SGAs, because studies have yielded discrepant results. A recent metaanalysis of FES trials (Crossley et al. 2010) showed no difference in efficacy between FGAs and SGAs. However, this meta-analysis included one non-randomized trial (Saddichha et al. 2007 ), failed to compare individual SGAs, investigated only two adverse effects and ignored important outcomes, including positive and negative symptoms, depression, cognitive functioning, specificcause discontinuation, long-term remission and relapse.
Therefore, we conducted a meta-analysis comparing the efficacy, effectiveness and adverse effects of primarily individual and secondarily pooled SGAs vs. FGAs in FES patients.
Method

Search
We conducted an electronic PubMed and Web of Science search (until 31 December 2010) for RCTs comparing FGAs vs. SGAs in first-episode patients with schizophrenia-spectrum disorders. The following key words were used : first episode ; first-episode psychosis ; first-episode schizophrenia ; early psychosis ; early schizophrenia ; recent onset ; recent onset psychosis ; recent onset schizophrenia ; antipsychotic(s) ; typical antipsychotic(s) ; conventional antipsychotic(s) ; neuroleptic(s) ; atypical antipsychotic(s) ; first-generation psychotics ; second-generation antipsychotic(s). We also screened reference lists from identified papers and reviews to identify additional studies. To find unpublished studies, we searched published meeting abstracts that were likely to contain relevant studies and contacted manufacturers of SGAs. Inclusion criteria were : (1) RCT with o1 FGA vs. SGA comparison ; (2) patients in their first episode of non-affective psychosis ; (3) diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder ; or psychosis NOS ; (4) data available for any of the following outcomes : efficacy, treatment discontinuation, weight gain, metabolic parameters, or cognition ; (5) acute treatment study. Maintenance studies were excluded, although long-term data from acute RCTs were included.
Data extraction and outcome variables
Data were independently extracted by two authors (J. P. Z., J. A. G.) ; any disagreement was resolved. For missing information, first and/or last study authors were contacted requesting additional/unpublished data. Short-term outcomes at 3 months (f13 wk) or closest follow-up time-point and long-term outcomes at about 6-24 months were analysed separately. Primary variables included the following three short-term outcomes : (1) allcause discontinuation ; (2) symptom reduction : changes in the Positive and Negative Syndrome Scale (PANSS ; Kay et al. 1987) or Brief Psychiatric Rating Scale (BPRS ; Overall and Gorham, 1962) total score from baseline ; (3) response rate : percentage of patients achieving 'clinical responder ' status at follow-up. We chose o50 % reduction in PANSS or BPRS total scores from baseline to follow-up as the preferred definition of clinical response, because this represents a clinically significant response (Leucht et al. 2007) . When this outcome was not available, study-defined response was used.
Secondary outcomes included last observation carried forward change from baseline in : (1) positive symptoms, measured by PANSS, Scale for the Assessment of Positive Symptoms (SAPS ; Andreason, 1984) or BPRS ; (2) negative symptoms, measured by PANSS or Scale for the Assessment of Negative Symptoms (SANS ; Andreason, 1983) ; (3) depressive symptoms, measured by a validated depression scale ; (4) Clinical Global Impressions-Severity (CGI-S) or improvement (Guy, 1976) score ; (5) cognitive functioning, measured by a composite score extracted from multiple neuropsychological tests. Categorical outcomes included : (6) discontinuation due to inefficacy ; (7) discontinuation due to intolerability ; (8) discontinuation due to non-adherence/patient choice ; (9) studydefined long-term (o1 yr) remission ; (10) long-term study-defined relapse and/or rehospitalization after achieving response. We also analysed common sideeffects : (11) EPS ; (12) akathisia ; (13) use of anticholinergic drugs, benzodiazepines and b-blockers, commonly used to manage antipsychotic side-effects ; (14) weight gain, as categorical and continuous variables ; (15) metabolic changes (total cholesterol, triglycerides, glucose).
The following study and patient characteristics were examined as moderators in meta-regression analyses : publication year ; number of sites ; blinding status ; study duration ; location (USA, Europe, Asia etc.) ; primary follow-up time-point ; study sponsorship (government-sponsored vs. industry-sponsored) ; sample size ; mean age ; percentage of males ; inpatient vs. outpatient status at randomization ; age at illness onset ; duration of psychosis ; diagnosis ; percentage of antipsychotic-naive patients (i.e. <2 wk lifetime exposure) ; baseline PANSS/BPRS total score ; baseline CGI-S score ; mean or modal antipsychotic dose (converted to haloperidol equivalents ; Woods, 2003 ; Lehman et al. 2004 ; Andreasen et al. 2010 ).
Statistical analysis
Outcomes were analysed separately using Comprehensive Meta-Analysis software version 2 (Biostat, USA). For continuous outcomes, Hedge's g was used as the effect size measure, representing standardized groups differences. For dichotomous outcomes, risk ratio (RR) was used as the effect size measure with FGAs as the reference group. The primary focus was individual drug comparisons. Pooled SGA-FGA comparisons were conducted to allow for meaningful moderator analyses across two antipsychotic classes that were contrasted in the literature previously. Pooled ES were computed with a random effects model (Borenstein et al. 2009 ). In each meta-analysis, a study was included only once to avoid redundancy. If a study had multiple eligible comparisons, the average ES was used in the FGA-SGA comparison. For individual antipsychotic comparisons, the FGA comparator was entered separately for each SGA.
Study heterogeneity was assessed using Q and I 2 statistics, with I 2 <25 % representing low, y50 % moderate and >75 % representing high heterogeneity (Borenstein et al. 2009 ). Whenever heterogeneity was present, moderator and meta-regression analyses were conducted to explore the effects of the moderators described earlier. Sensitivity analyses were conducted to assess potential influences of any one single study on the pooled ES. Within each meta-analysis, included studies were removed individually to check for significant alterations to pooled ES and associated p values. Moreover, we assessed for an influence of sponsorship bias (government vs. industry) and of age group (in-or excluding the only trial conducted in adolescents, i.e. TEOSS ; Sikich et al. 2008) .
Publication bias was assessed with the funnel plot, Egger's regression test (Egger et al. 1997 ) and the 'trim and fill' method (Duval and Tweedie, 2000) , an iterative procedure to assess whether small, extreme included studies and/or potentially unincluded studies biased the true ES estimate.
Results
Search and study characteristics
Of 776 hits, 22 papers reporting on 13 independent cohorts (Emsley, 1999 ; Sanger et al. 1999 ; de Haan et al. 2003 ; Lieberman et al. 2003a,b ; Fagerlund et al. 2004 ; Schooler et al. 2005 ; Crespo-Facorro et al. 2006 ; Wu et al. 2006 ; Lee et al. 2007 ; Kahn et al. 2008 ; Moller et al. 2008 ; Sikich et al. 2008 ) and 20 comparisons across 12 individual SGA-FGA pairs (n=2509) were identified ( Supplementary Fig. S1 ) and meta-analysed. Three trials included in a prior meta-analysis on this topic (Crossley et al. 2010) were excluded due to non-randomized design (Saddichha et al. 2008) , skewed data (Brewer et al. 2007 ) and absence of meta-analysable data (Bustillo et al. 2008) . The mean study duration was 32.1¡36.6 (range : 6-104) wk, mean age 27.1 yr, 69.5 % were male and the mean baseline PANSS total score was 85.8¡8.8 (Supplementary Table S1 ). Five studies each compared olanzapine vs. haloperidol (Sanger et al. 1999 ; de Haan et al. 2003 ; Lieberman et al. 2003b ; Crespo-Facorro et al. 2006 ; Kahn et al. 2008 ) and risperidone vs. haloperidol (Emsley, 1999 ; Schooler et al. 2005 ; Crespo-Facorro et al. 2006 ; Lee et al. 2007 ; Moller et al. 2008) . The other 10 SGA-FGA comparisons were examined in one study each.
Nine studies (69 %) were double-blinded, four were open label (Fagerlund et al. 2004 ; Crespo-Facorro et al. 2006 ; Wu et al. 2006 ; Kahn et al. 2008) . Eight studies (62 %) were short-term (f13 wk), five lasted o1 yr. The most commonly studied FGA was haloperidol (nine studies, 69 %) ; and one study each included chlorpromazine (Lieberman et al. 2003a) , molindone (Sikich et al. 2008) , sulpiride (Wu et al. 2006 ), or zuclopenthixol (Fagerlund et al. 2004 ). The most commonly studied SGAs (where N=number of studies) were risperidone (N=8) and olanzapine (N=7), followed by clozapine (N=2) and quetiapine, ziprasidone and amisulpride (N=1 each ; Kahn et al. 2008) . The number of patients per trial ranged from 24 to 555. At baseline, most studies reported a diagnosis of schizophrenia in >50 % of patients, except for two trials (Emsley, 1999 ; Schooler et al. 2005) . The mean duration of psychosis ranged from 13 to 18.4 months, except for one study (Wu et al. 2006) where it was 2.6 months. The mean age of illness onset ranged from 23 to 27 yr, except for the TEOSS study (Sikich et al. 2008 ), which, due to its design, had a mean age of onset of 11.1 yr. Pharmaceutical companies sponsored 54 % of the studies, with government agency sponsorship of the remaining trials. The proportion of antipsychotic-naive subjects at baseline ranged from 8.3 to 100 % (mean : 62.7 %). Among nine studies with data on response, three used a o50 % cut-off as the responder definition, three used o40 % and three used either o30 % or o20 %.
Primary outcomes
Short-term all-cause discontinuation Olanzapine (RR=0.53, p=0.001, N=5, n=689) and risperidone (RR=0.79, p=0.03, N=4, n=1146) caused less all-cause discontinuation than haloperidol (Table 1 ; First-episode psychosis treatment meta-analysis 1207 Supplementary Fig. S2 ). Among single-trial comparisons, only amisulpride was superior to haloperidol (RR=0.63, p<0.01). Pooled SGAs had significantly lower discontinuation rates than FGAs (RR=0.74, p<0.001, N=10, n=1952). Pooled risk difference was x0.08 [95 % confidence intervals (CI)=x0.14 to x0.02, number needed to treat (NNT)=12, p<0.01]. No moderating variables were found.
Short-term total symptom reduction
Only olanzapine (ES=0.26, p=0.01, N=5, n=676) and amisulpride (ES=0.40, p<0.01, N=1) were superior to haloperidol (Table 1 ; Supplementary Fig. S3 ). Pooled SGAs showed only trend-level superiority compared to FGAs (ES=0.11, p=0.09, N=12, n=1951). Study sponsorship significantly moderated the effect (Q=6.68, p=0.01). Government-sponsored studies trended in favour of FGAs (ES=x0.10, p>0.10, N=5, n=525), while industry-sponsored studies significantly favoured SGAs (ES=0.19, p=0.007, N=7, n=1,426 ; Supplementary Fig. S4 ). The EUFEST trial (Kahn et al. 2008 ) was investigator-designed and then sought industry funding, but excluding EUFEST did not significantly alter the results. No other significant moderator emerged.
Short-term response
Only olanzapine (RR=1.29, p=0.02, N=4, n=652) and amisulpride were superior to haloperidol (RR=1.56, p<0.01, N=1 ; Table 1 ; Supplementary Fig. S5 ). Pooled SGAs were marginally better than FGAs (RR=1.13, p=0.06, N=9, n=1,724). Excluding the TEOSS study (Sikich et al. 2008 ) conducted in adolescents resulted in a significant RR favouring SGAs (RR=1.14, 95 % CI=1.02-1.29, p=0.026). Again, industry-sponsored studies showed higher response for SGAs (RR=1.23, 95 % CI=1.06-1.42, p=0.005), while non-industry-sponsored studies did not (RR=0.97, 95 % CI=0.81-1.16, p=0.75), with significant sponsorship effect (Q=3.97, p=0.046 ; Supplementary Fig. S6 ). There was no other significant moderator.
Long-term primary outcomes
Individual SGAs vs. FGAs were similar regarding longterm all-cause discontinuation, but pooled results still trended favouring SGAs (RR=0.78, 95 % CI=0.60 to 1.01, p=0.06, N=5, n=1133). Neither long-term symptom reduction (ES=0.01, 95 % CI=x0.11 to 0.14, p>0.10, N=4, n=953) nor long-term response (RR=1.05, 95 % CI=0.95 to 1.16, p>0.10, N=5, n=1133) differed in individual or pooled SGA-FGA comparisons.
Secondary outcomes
Positive symptoms
No significant difference emerged between SGAs and FGAs, except that amisulpride outperformed haloperidol (Table 2 ). Olanzapine had trend-level superiority (ES=0.26, p=0.08, N=4, n=653). Pooled SGA-FGA comparison also revealed no significant difference.
Negative symptoms
Several SGAs outperformed their FGA comparators (Table 2 ) including olanzapine vs. haloperidol (ES=0.30, p<0.001, N=4, n=653), quetiapine vs. haloperidol Number of studies (N) and sample size (n) are the largest possible for each comparison pair, but N and n for each outcome may vary. * p<0.05 ; ** p<0.01. Supplementary Fig. S7 ).
Depression
Only olanzapine (ES=0.28, p=0.001, N=4, n=565) and amisulpride (ES=0.32, p<0.05) outperformed haloperidol (Table 2) . Pooled SGAs showed trend-level superiority over FGAs (ES=0.12, p=0.06, N=6, n=1376). However, again, industry-sponsored studies more likely favoured SGAs.
Clinical global impressions-severity
Only amisulpride was superior to haloperidol (ES=0.38, p<0.01). Pooled SGAs and FGAs were also similar (N=6, n=1038, Table 2 ). Again, industry-sponsored studies were more likely to favour SGAs.
Global cognition
Olanzapine (ES=0.27), risperidone (ES=0.23) and pooled SGAs (ES=0.25, p=0.001, N=5, n=693) were superior to FGAs in improving cognitive composite scores at 3-6 months ( Table 2 , Supplementary Fig. S8 ).
Specific-cause discontinuation
Olanzapine (RR=0.38, p<0.001), amisulpride (RR=0.24, p<0.01) and pooled SGAs (RR=0.60, p=0.001, N=9, n=1792) led to less discontinuation due to inefficacy than FGAs (Table 3) . Olanzapine (RR=0.29, p=0.001), risperidone (RR=0.50, p=0.02), quetiapine (RR=0.13, p<0.01) and pooled SGAs (RR=0.46, p<0.001, N=8, n=1768) led to less discontinuation due to intolerability than the FGA comparator. Only quetiapine led to less discontinuation due to patient decision/non-adherence than haloperidol (RR=0.15, p<0.05), without differences in pooled SGA-FGA comparisons.
Long-term remission and relapse rates
Regarding long-term remission, olanzapine (RR=1.57, p=0.03) and amisulpride (RR=2.35, p=0.001) were superior to haloperidol. Pooled SGAs (N=4, n=740) showed only trend-level advantage over FGAs (RR= 1.26, p=0.06 ; Table 3 ). However, risperidone (RR=0.77, p=0.01), ziprasidone (RR=0.32, p=0.03) and pooled SGAs (RR=0.84, p=0.04, N=6, n=1092 ; Table 3 ), had lower relapse rates than FGAs. Long-term discontinuation due to inefficacy was lower with olanzapine than haloperidol (RR=0.51, 95 % CI=0.27-0.95, p=0.04, N=3, n=582), but pooled SGA-FGA comparisons were non-significant (RR=0.66, 95 % CI=0.37-1.17, p=0.16, N=5, n=1295). Regarding long-term discontinuation due to intolerability, olanzapine outperformed haloperidol (RR=0.31, p<0.001) and SGAs outperformed FGAs (RR=0.49, CI=0.32-0.75, p=0.001, N=5, n=1295).
Adverse events
EPS and akathisia-related outcomes EPS was less frequent and severe in patients on several SGAs than their FGA comparators, including olanzapine (ES=x0.69, p<0.001, N=4, n=609) and risperidone (ES=x0.33, p<0.001, N=3, n=588) compared to haloperidol and clozapine compared to chlorpromazine (ES=x0.72, p<0.01), although all patients on chlorpromazine received prophylactic benztropine (Table 4) . Pooled SGAs produced significantly less EPS than FGAs (ES=x0.43, p<0.001, N=9, n=1338). Two significant moderators emerged : more recent studies had smaller SGA-FGA differences in EPS (b=0.04, p=0.02) ; conversely, higher patient age was associated with larger ES (b=x0.04, p=0.006). At long-term follow-up, SGAs still produced less EPS (RR=0.42, CI=0.24-0.73, p=0.002, N=2, n=319).
Short-term akathisia was also less likely with olanzapine (ES=x0.61, p<0.05) and risperidone (ES=x0.29, p<0.05) and with pooled SGAs vs. FGAs (ES=x0.48, p<0.001, N=7, n=998 ; Table 4 ). At 1-2-yr follow-up, akathisia was still less severe/prevalent with SGAs (ES=x0.33, 95 % CI=x0.48 to x0.19, p<0.001, N=4, n=930).
Compared to haloperidol, patients on olanzapine took less anticholinergics (RR=0.21, p<0.001, N=3, n=445), benzodiazepines (RR=0.83, p=0.02, N=3, n=445) and b-blockers (RR=0.11, p<0.01, N=1, n=251 ; Table 4 ). Olanzapine was also superior to molindone regarding less anti-cholinergic co-administration (RR=0.31, p<0.01), although all patients on molindone received prophylactic benztropine (Table 4) . Pooled SGAs were associated with less anticholinergic (RR=0.47, p<0.01, N=6, n=999) and benzodiazepine use (RR=0.84, p<0.01, N=5, n=999 ; Table 4 ). Moderator analyses revealed that in open-label studies more patients on FGAs took anticholinergics than in double-blind studies. Significantly less anticholinergic use with SGAs than FGAs was associated with smaller sample size, younger age, male sex and longer follow-up. SGAs and FGAs did not differ regarding b-blocker use.
At 1-2-yr follow-up, SGAs were still associated with less anticholinergic use than FGAs (RR=0.55, 95 % CI=0.34-0.88, p=0.01, N=4, n=1,083). Conversely, benzodiazepine use did not differ between SGAs and FGAs (RR=0.91, 95 % CI=0.80-1.03, p=0.14, N=3, n=820). Only one study reported long-term b-blocker use (n=555), showing lower use with risperidone than haloperidol (RR=1.48, 95 % CI=0.26-0.88, p=0.02). Number of studies (N) and sample size (n) are the largest possible for each comparison pair, but N and n for each outcome may vary. * p<0.05 ; ** p<0.01. Co-meds, Co-occurent medication ; N, number of studies ; n, sample size. * p<0.05 ; ** p<0.01. a In the TEOSS study, all patients on molindone were also given 1 mg benztropine daily by study design, but some patients received additional benztropine due to side-effects. Calculation of effect size was based on number of patients on molindone who received additional benztropine. b In Lieberman et al.'s (2003a,b) clozapine vs. chlorpromazine study all patients on chlorpromazine also took 2 mg benztropine twice daily by study design.
A negative effect size and a relative risk (RR) <1 indicate worse side-effects from FGAs.
Weight and metabolic outcomes
Olanzapine increased weight significantly more than haloperidol, molindone and sulpiride (ES=0.61-3.56 ; Table 5 ). Risperidone also caused significantly more weight gain than haloperidol and molindone (ES=0.22-0.93). Clozapine was associated with more weight gain than sulpiride (ES=4.95) in one study. Pooled SGAs caused more weight gain than FGAs (ES=0.65, p<0.001, N=7, n=1059). Moderator analysis revealed that larger differences in weight gain between SGAs and FGAs were associated with shorter follow-up time, smaller sample size, younger age, female sex and schizophrenia diagnosis. While at long-term follow-up SGAs were still associated with more weight gain than FGAs (N=5, n=996), the ES was about halved (pooled ES=0.33, 95 % CI=0.07-0.59, p=0.01). Likewise, weight gain o7 % was significantly more likely with olanzapine (RR=3.31, p<0.01) and risperidone (RR=1.61, p<0.01) than haloperidol and with SGAs than FGAs [RR=2.26, 95 % CI=1.33-3.69, p=0.001, number needed to harm (NNH)=4, N=3, n=733 ; Table 5 ]. Weight gain o7 % during long-term follow-up was still more likely with SGAs than FGAs, but the RR was smaller (RR=1.45, 95 % CI=1.17-1.79, p=0.001, NNH=5.35, N=3, n=778). Olanzapine, risperidone and clozapine were associated with lower glucose change than sulpiride in one study (Wu et al. 2006 ). Compared to haloperidol, glucose changes were similar with olanzapine, risperidone, amisulpride and quetiapine haloperidol ; only ziprasidone was significantly better than haloperidol in one study (ES=x0.36, p<0.05 ; Table 5 ). Pooled SGAs and FGAs were similar (ES=x0.16, 95 % CI=x0.57 to 0.25, p=0.44, N=6, n=749). Heterogeneity across studies was high (Q=36.10, p<0.001, I
2 =86.15 %). Even when excluding an outlier (Wu et al. 2006) , pooled ES remained non-significant. No SGA-FGA difference emerged regarding long-term glucose change (N=3).
Regarding short-term total cholesterol change, olanzapine was significantly worse than molindone and sulpiride and marginally worse than haloperidol (ES=0.17, p=0.051, N=3, n=501 ; Table 5 ). Risperidone was not different from haloperidol, but significantly better than sulpiride. Pooled SGAs were associated with a marginally larger total cholesterol increase than FGAs (ES=0.46, p=0.053, N=5, n=593). Heterogeneity was large (Q= 24.64, p<0.001, I
2 =83.76 %). Excluding Wu et al. (2006) resulted in a much smaller ES (ES=0.15, p=0.08). No significant SGA-FGA difference emerged regarding longterm cholesterol change (N=2).
Only few studies reported on triglyceride changes. Olanzapine and clozapine were worse than sulpiride and amisulpride was worse than haloperidol. However, risperidone was better than sulpiride (Table 5) . Pooled SGAs showed marginally greater short-term triglyceride increase than FGAs (ES=0.71, p=0.057, N=4, n=371). Heterogeneity was high (Q=25.54, p<0.001, I
2 =88.25 %).
Excluding Wu et al. (2006) the pooled ES became much smaller (ES=0.20, p=0.08).
Discussion
In this comprehensive meta-analysis of head-to-head trials, several SGAs outperformed FGAs in FES patients : olanzapine, amisulpride and risperidone were associated with significantly lower treatment discontinuation rates ; olanzapine and amisulpride were superior regarding dropout due to inefficacy ; olanzapine, risperidone and quetiapine led to less dropouts due to intolerability. Only quetiapine had less discontinuation due to nonadherence/patient choice. Pooled together, SGAs vs. FGAs had lower treatment discontinuation rates due to any cause (NNT=12), inefficacy and intolerability reducing these events by 26, 40 and 54 %, respectively ( Supplementary Fig. S9 ). Regarding total symptom reduction, only olanzapine and amisulpride outperformed FGAs and FGA-SGA class differences were nonsignificant. Moreover, olanzapine outperformed haloperidol on negative symptoms, depression, global cognition and long-term remission ; amisulpride outperformed haloperidol regarding positive symptoms, depression, CGI-S and long-term remission ; clozapine and quetiapine each outperformed chlorpromazine and haloperidol regarding negative symptoms, while risperidone and ziprasidone had lower relapse rates. Pooled SGAs outperformed FGAs on negative symptoms (ES=0.16), global cognition (ES=0.25) and relapse ( Supplementary  Fig. S9 ). Interestingly, some of the important factors in treating first-episode psychosis such as haloperidol equivalent dosing and percentage of drug-naive patients were not significant in moderator analysis of any outcome. The same was true for blinding status. Notably, however, government-sponsored studies tended to favour FGAs, whereas industry-sponsored studies tended to favour SGAs in total symptom reduction and response rate. While being a post hoc finding, it is possible that in industry-sponsored studies raters had a subtle bias against FGAs, especially when EPS unmasked drug assignment, but more independently funded studies are needed.
Results of drug-induced adverse events were robust and ES were large. Olanzapine, risperidone, clozapine and pooled SGAs caused significantly less EPS, akathisia and/or co-treatment with anticholinergics and benzodiazepines than FGAs. Conversely, clozapine, olanzapine, risperidone and pooled SGAs showed larger weight gain than FGA comparators, but without significantly greater increases in glucose and lipid parameters, except for isolated findings with clozapine, olanzapine and amisulpride, at least in these shorter-term trials.
First-episode patients are especially sensitive to druginduced side-effects including EPS and weight gain. Therefore, the lower EPS risk with most SGAs, also found in chronic patients (Fischer-Barnicol et al. 2008) , is First-episode psychosis treatment meta-analysis 1213 beneficial. Interestingly, in more recent studies, the ES favouring SGAs has been diminishing. This is likely attributable to lower FGA comparator doses and less uniform use of haloperidol. The fact that older subjects showed greater FGA-SGA differentiation is consistent with the fact that young and paediatric patients are at particular risk for EPS, even with SGAs (Correll et al. 2006) . Consistent with data in chronic patients, continuous and categorical 'significant ' weight gain outcomes disfavoured most SGAs being more pronounced in younger patients, females and schizophrenia patients. That schizophrenia emerged as a risk factor suggests that illness severity and/or negative symptoms might also play a role in weight gain. The lack of glucose differences (except for a favourable outcome with ziprasidone) is not surprising, since (pre)diabetes generally emerges only after a period of insulin resistance (de Hert et al. 2011) and insulin levels were not measured. Moreover, since mostly short-term results were available, longer-term risk for more distal outcomes, such as diabetes and cardiovascular illness, were not available in first-episode patients, except for a data base study (Nielsen et al. 2010 ). Interestingly, SGA-FGA ES differences for weight and lipid outcomes declined with longer follow-up, suggesting that non-medication effects, such as unhealthy lifestyle, the underlying illness, environment and possibly, genetics, start playing a relevant role.
Taken together, these meta-analytic results confirm that SGAs are not a homogeneous class, being associated with different efficacy and side-effect profiles (Leucht et al. 2009 ; Kane and Correll, 2010) . Notably, like a prior meta-analysis in chronic schizophrenia (Crossley et al. 2010) , we also found small ES differences favouring amisulpride and olanzapine and, less so, risperidone compared to FGAs. The superior outcome regarding a global cognitive index with olanzapine and risperidone compared to FGAs, even given at relatively low doses, is noteworthy, being inconsistent with chronic schizophrenia data (Keefe et al. 2007 ). The potential for greater treatment differences in earlier illness phases, although unclear to date, deserves follow-up, as cognitive dysfunction has been associated with poor functional outcomes (Brekke et al. 2007 ). However, the superiority of olanzapine, risperidone and amisulpride, but not of other SGAs, compared to FGAs could be due to a cohort effect, in that these three SGAs were studied earlier, at a time when higher haloperidol were commonly used, causing potentially higher drop-out rates. In fact, in our analyses EPS differences between SGAs and FGAs diminished over time. Moreover, during the past decade ES have decreased in schizophrenia and central nervous system trials in general . Nevertheless, neither FGA comparator doses nor year of study publication emerged as significant moderators in any analyses. Another interesting finding is that clozapine was not more efficacious or effective than chlorpromazine in FES patients. This is inconsistent with chronic schizophrenia data, but confirmed the notion that clozapine should be reserved for treatment of refractory schizophrenia due to its significant side-effect profile. However, these results were based on one single study conducted in Chinese patients ; yet additional FES studies with clozapine are unlikely to be conducted due to its significantly more severe side-effect burden and the overall greater responsiveness of FES patients compared to chronic patients.
Nevertheless, overall, ES of the efficacy differences, either in pooled or individual analyses, were relatively small, with the exception of significantly lower all-cause and specific-cause discontinuation rates with SGAs. This suggests that FES patients who are generally more treatment responsive than chronic patients have a reasonable chance of benefiting from any antipsychotic treatment. By contrast, side-effect differences were larger. Therefore, antipsychotic choice should take into consideration the safety profile of each agent and the patient's willingness to accept specific adverse effect clusters. Moreover, the robust finding of lower treatment discontinuation with SGAs is quite relevant, given that engagement and continued antipsychotic treatment are crucial for relapse prevention, remission, recovery and other beneficial outcomes (Kane and Correll, 2010) . It is unclear, however, if the lower treatment discontinuation was affected by less frequent EPS and akathisia compared to FGAs, as patient choice-related discontinuation did not differ between SGAs and FGAs, except for quetiapine which has particularly low EPS and akathisia rates. Nevertheless, the coding of reasons for treatment discontinuing treatment mostly lacked detail. Furthermore, despite the neuromotor adverse effect advantage of SGAs, significant weight gain induced by SGAs, especially olanzapine and clozapine, but also risperidone, is of major concern for patients ' long-term health (Correll et al. 2009 ). More studies are needed to better understand predictors of antipsychotic-induced weight gain, including genetic markers.
Several limitations of the present study require consideration. The number of relevant RCTs in first-episode patients was small and some outcomes were not reported by all studies. Only one study was available for amisulpride, quetiapine and ziprasidone and studies were missing for aripiprazole, asenapine, iloperidone, lurasidone and paliperidone. Therefore, specific drug recommendations should be viewed with caution. Moreover, studies included in any meta-analysis are heterogeneous, but we used random effects models and performed sensitivity and moderator analyses to deal with this limitation. In addition, haloperidol was used as the SGA comparator in 9/13 studies and was frequently used in relatively high doses. This might have caused higher EPS and discontinuation rates, although haloperidol dose was not a significant moderator in our analyses. Moreover, most data were available for short-term outcomes and data on TD were generally lacking. Also, unmeasured medication non-adherence may have affected these findings. Finally, head-to-head trials comparing SGAs with SGAs in FES were not included, being beyond the scope of this meta-analysis.
In summary, in FES, pooled SGAs were either similarly effective or modestly better than FGAs regarding several efficacy and tolerability outcomes, being associated with greater weight gain. Among individual SGAs, amisulpride and olanzapine and, to a lesser degree, risperidone were most consistently superior to their respective FGA comparator, but weight and metabolic problems were also greater with olanzapine. Overall, risperidone appears to be reasonably efficacious and is associated with relatively benign side-effects, so it should be considered as a first-line therapy for first-episode schizophrenia. However, studies with aripiprazole and newer SGAs that generally have less metabolic liability (de Hert et al. 2012) are clearly needed and mid-potency FGAs should strongly be considered as comparators. Furthermore, since SGAs were significantly superior for negative symptom, global cognition and long-term relapse outcomes compared to FGAs, future studies need to study the real world functional implications of these potential differences and include subjective well-being and costeffectiveness outcomes to inform broader health care strategies and resource allocation.
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